Cargando…
XG-102 administered to healthy male volunteers as a single intravenous infusion: a randomized, double-blind, placebo-controlled, dose-escalating study
The aim of the study is to evaluate the safety, tolerability and pharmacokinetics (PK) of the JNK inhibitor XG-102 in a randomized, double blind, placebo controlled, sequential ascending dose parallel group Phase 1 Study. Three groups of male subjects received as randomly assigned ascending single X...
Autores principales: | Deloche, Catherine, Lopez-Lazaro, Luis, Mouz, Sébastien, Perino, Julien, Abadie, Claire, Combette, Jean-Marc |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4186400/ https://www.ncbi.nlm.nih.gov/pubmed/25505576 http://dx.doi.org/10.1002/prp2.20 |
Ejemplares similares
-
The JNK Inhibitor XG-102 Protects against TNBS-Induced Colitis
por: Reinecke, Kirstin, et al.
Publicado: (2012) -
Model-Informed Development of Sotalol Loading and Dose Escalation Employing an Intravenous Infusion
por: Somberg, John C., et al.
Publicado: (2020) -
Dasiglucagon Effects on QTc in Healthy Volunteers: A Randomized, Placebo-Controlled, Dose-Escalation, Double-Blind Study
por: Tehranchi, Ramin, et al.
Publicado: (2022) -
Bayesian auction game theory-based DBA for XG symmetrical PON
por: Hussain Mohammadani, Khalid, et al.
Publicado: (2022) -
CNN-XG: A Hybrid Framework for sgRNA On-Target Prediction
por: Li, Bohao, et al.
Publicado: (2022)